UK plan for fast-tracking safe COVID-19 vaccines

29 August 2020

Although there is no assurance that an acceptably safe and effective vaccine against COVID-19 will be developed this side of the UK’s final Brexit on December 31, the British medicines regulator has announced a raft of measures for approving such a product without waiting for a decision from the European Medicines Agency.

The measures announced on Friday (August 28) include:

reinforced safeguards to support the Medicines and Healthcare products Regulatory Agency (MHRA) to grant temporary authorization for the use of a new COVID-19 vaccine ‒ provided it meets the highest safety and quality standards;
expanding the trained workforce who can administer COVID-19 and flu vaccines to improve access and protect the public; and
clarifying the scope of the protection from civil liability for the additional workforce that could be allowed to administer vaccinations

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK